Amgen Gobbles Up Micromet In $1.16 Billion BiTE
This article was originally published in The Pink Sheet Daily
With the acquisition of Micromet, Amgen gains a Phase II asset for hard-to-treat hematologic malignancies and a promising antibody platform known as Bispecific T cell Engager (BiTE).
You may also be interested in...
Cancer immunotherapy biotech Leap, backed by HealthCare Ventures and Lilly, reverse-merges with Israel's Macrocure. Elite and SunGen will partner to develop generic versions of four drugs that posted $3bn in aggregate sales over a recent 12-month stretch.
The acute lymphoblastic leukemia therapy, already available in the US, was recommended for a conditional approval in Europe to speed early patient access.
The big biotech’s blinatumomab gains accelerated approval to treat a rare form of ALL. The breakthrough therapy does have a REMS on serious risks and administration concerns.